TAT2005 - 3rd International Symposium on Targeted Anticancer...( The 3rd International Symposium on Targ...)

The 3rd International Symposium on Targeted Anticancer Therapies (TAT 2005) will be held in Amsterdam, The Netherlands, March 3-5, 2005. This conference will provide an update of recent developments concerning the new generation of rationally designed anticancer agents with well defined molecular targets in the cancer cell or the cancer cell's environment: targeted agents. The first representatives of this new generation of cancer therapies, including bevacizumab (Avastin), cetuximab (Erbitux) and bortezomib (Velcade), have already been approved for the treatment of cancer patients. In addition, dozens of other targeted agents are in various stages of clinical development. It is expected that several of these agents will obtain regulatory approval in the (near) future. Thus, TAT 2005 will provide a view of the future of cancer therapy.

Among the highlights of TAT 2005 will be the Keynote Lectures on March 3. One of these keynotes, the 2005 NDDO Honorary Lecture (Thursday, March 3, 2005; 13:15-13:55 hours), will be presented by Professor Daniel D. Von Hoff of the University of Arizona. He will address the question why certain cancer patients respond well to targeted agents, whereas others do not. Professor Von Hoff is one of the leading pioneers in the development of this new generation of anticancer agents.

Another highlight of the TAT 2005 program will be a Plenary Session on Friday, March 4 (8:30-10:30 hours) on emerging treatment options for renal cell cancer. Remarkably, several new targeted agents show good results in clinical studies in patients with metastasized renal cell cancer, a disease with very few effective treatment options today. The Plenary Session on March 4 will feature six promising new agents, which will be reviewed and discussed by internationally renowned clinical experts who have hands-on experience with these agents in clinical trials.

The meeting program will also cover updates on the continued clinical development
'"/>

Contact: Marinus Lobbezoo
congress@nddo.org
31-356-910-052
European Society for Medical Oncology
3-Mar-2005

Page: 1 2
Related biology news :

1. National Ecological Observatory Network featured at ESA/SER Joint International Conference
2. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
3. 2nd International EuroFIR Congress
4. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
5. Smithsonian hosts Polar Science Symposium to celebrate International Polar Year 2007-2008
6. Eduardo Slatopolsky honored with 2007 ISN Amgen International Prize
7. 4th International Conference on Ethical Issues in Biomedical Engineering
8. International risk research strategy and funding needed for nanotech safety
9. Pezcoller Foundation-AACR International Award for Cancer Research recognizes Mina J. Bissell
10. International Astronautical Federation joins project to protect World Heritage sites
11. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions